Our particular drug is the most potent of all those that are out there. And as a result of that it could be administered in a very small volume and we anticipate that will be less than 1 ml of fluid given once per month subcutaneously. It’s also quite stable which will allow us to ultimately have this available for self-administration. As far as I know it’s the only one that’s out there. And we have seen virtually no injection side reactions, which again, if you look at the label of the competitors, in no case are they devoid of injection side reactions. So that’s potentially another advantage.
So I think from it’s both physical and [chemical] characteristics and its potency and its ease of use, plus its mechanism, it’s clearly distinct from the other candidates or the drugs that are out there.
Yigal Nochomovitz - Morgan Stanley
You mentioned the lead indication and you are in non-infectious uveitis, you have also seen some solid data in related form of that disease called the Behçet's. Could you discuss a bit some of the data there and whether the mechanism that you have described for your gevokizumab is special for that disease or if other INLINE-1 antibodies could potentially show efficacy in that setting.Paul Rubin That’s a good question. First of all, uveitis is a syndrome, not unlike asthma, in which there are multiple (inaudible), Behçet's uveitis being one. So in fact Behçet's isn’t related, it is not infectious uveitis, it’s just one of the forms. In all cases, independent of the underlying [mediology], it presents clinically in the same way. So all cases they end of with inflammation of the uvea, which is kind of the middle lining around the eye. And as a result of that inflammation, they end up with the same clinical signs and symptoms. And in fact in the United States, the FDA doesn’t discern between Behçet's uveitis and other forms. It’s all non-infectious uveitis. Read the rest of this transcript for free on seekingalpha.com
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV